Oxford Biomedica Solutions
Stacy Ota is a Senior Research Associate at Oxford Biomedica, having transitioned from the role of Research Associate II following the company's acquisition of Homology Medicines in March 2022, where Stacy also held the position of Research Associate II from July 2019. Prior experience includes serving as Research Associate I and Laboratory Manager at Fulcrum Therapeutics and as a Laboratory Operations Associate at Thermo Fisher Scientific, where Stacy worked as a Senior Site Specialist. Stacy Ota earned a Bachelor of Science degree from Boston University.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.